Thats why we decided to write this book.
IGF-1 DES shows moderately reduced IGFBP affinity, with greater selectivity it particularly reduces affinity for IGFBP-1, IGFBP-2, and IGFBP-4, but retains more binding to IGFBP-3 than IGF-1 LR3 does
[1] [2] The medication works by mimicking the action of the naturally occurring hormone GLP-1, which stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, and reduces appetite through central nervous system pathways
At two years, liraglutide and mid-dose phentermine and topiramate were strictly dominated by top-dose phentermine and topiramate
This is still clearly a work in progress, though
But this combination has never been studied, and using one peptide to counteract the side effects of another peptide is a regimen that demands physician oversight